electroCore, Inc. filings document the regulatory record of a commercial-stage bioelectronic medicine and wellness company focused on non-invasive vagus nerve stimulation products. Current reports include financial results, guidance, preliminary estimates, and business updates tied to prescription sales, VA channel activity, direct-to-consumer Truvaga sales, and Quell product revenue.
The filings also cover capital-structure and governance matters, including common stock issuances, resale registration obligations, board composition, executive changes, and related material-event disclosures. These records describe electroCore’s operating performance, product commercialization, financing activity, and public-company governance framework.
electroCore, Inc. reported third-quarter 2026 net sales of $9.690 million, up 12% from $8.689 million a year earlier, while net loss narrowed to $1.339 million from $3.405 million. For the first nine months, sales were $28.724 million versus $22.789 million, and net loss was $9.669 million versus $10.931 million.
Cash, cash equivalents and marketable securities totaled $7.5 million at September 30, 2026. Operating activities used $9.355 million during the nine months, compared with $6.647 million a year earlier. Management said forecast cash falls short of planned operating, investment and capital-expenditure needs for at least the next 12 months from issuance, raising substantial doubt about the company’s ability to continue as a going concern. Lovell represented 62.6% of third-quarter net sales; beginning in August 2026, electroCore implemented a change to transition all prescription product sales to the VA and Department of Defense through Lovell.
In October 2026, electroCore submitted a 510(k) premarket notification seeking FDA clearance of Quell for chronic chemotherapy-induced peripheral neuropathy. Under its Sales Agreement, the company sold 505,346 shares during the nine months for approximately $4.0 million in net proceeds after $0.3 million in issuance costs.
electroCore, Inc. (ECOR) reported third-quarter 2026 net sales of $9.7 million, up approximately 12% from $8.7 million a year earlier. GAAP net loss narrowed to $1.3 million from $3.4 million, while Adjusted EBITDA net loss improved to $0.7 million from $2.0 million. U.S. prescription revenue grew approximately 25% in the quarter. Approximately 17,700 VA patients had received a gammaCore device, representing approximately 3.0% penetration of the estimated addressable VA headache market.
The company revised full-year 2026 revenue guidance to $39 million to $42 million, from prior guidance of greater than 30% revenue growth. Its preliminary 2027 outlook calls for 30% to 40% revenue growth over full-year 2026 revenue, and it expects its first quarter with positive Adjusted EBITDA by the end of 2027. In October, electroCore submitted a 510(k) premarket notification seeking FDA clearance of Quell for chronic chemotherapy-induced peripheral neuropathy. Cash, cash equivalents and marketable securities totaled approximately $7.5 million as of September 30, 2026, compared with approximately $11.6 million at December 31, 2025.
electroCore, Inc. (ECOR) director Thomas J. Errico reported purchasing 5,000 shares of Common Stock on September 14, 2026 in an open-market or private transaction at a weighted-average price of $9.8163 per share, with individual trade prices ranging from $9.60 to $9.84.
After this transaction, Errico beneficially owns 363,904 shares, including directly held shares, shares held in family and personal trusts, and both vested and unvested Deferred Stock Units. The report states it was filed late due to an inadvertent administrative oversight and that no Rule 10b5-1 trading plan is indicated.
electroCore, Inc. (ECOR) disclosed that Co-Chief Executive Officer, President and Chief Operating Officer Michael Fox filed an amended Form 4 to correct the transaction code for a recent purchase. On September 11, 2026 he purchased 5,000 shares of common stock at an average price of $9.8007 per share in an open-market or private transaction, bringing his reported direct holdings to 130,000 shares. This total includes 125,000 shares issuable pursuant to previously granted restricted stock units that vest in scheduled annual installments between April 13, 2027 and September 8, 2029, subject to continued service and with accelerated vesting upon certain termination events following a change in control under the company’s Executive Severance Policy.
electroCore, Inc. (symbol: ECOR) is the issuer of record for a Form 4 filing submitted to the SEC. Fox Michael reported acquisition or exercise transactions in this Form 4 filing.
electroCore, Inc. (ECOR) reported that Co-Chief Executive Officer, President and Chief Operating Officer Michael Fox received a grant of 5,000 shares of Common Stock on September 11, 2026 at a reported value of $9.8007 per share, bringing his reported direct holdings to 130,000 shares. This total includes 125,000 shares issuable under previously granted RSUs, which vest in scheduled tranches from April 13, 2027 through September 8, 2029, subject to continued service, with full acceleration upon certain terminations within two years after a change in control under the company’s Executive Severance Policy. No Rule 10b5-1 trading plan is reported for this transaction.
electroCore, Inc. (symbol: ECOR) is the issuer of record for a Form 4 filing submitted to the SEC. Theofilos James Charles reported acquisition or exercise transactions in this Form 4 filing.
electroCore, Inc. (ECOR) reported that director James Charles Theofilos received a grant of 11,123 Restricted Stock Units (RSUs) on September 9, 2026 as part of an annual director equity award. These RSUs vest in 12 equal monthly installments from the grant date, with full vesting instead occurring earlier if service continues through the business day before the next annual stockholder meeting or immediately prior to a change of control. After this grant, Theofilos holds 34,670 equity interests, consisting of 7,385 vested RSUs, 25,894 unvested RSUs, and 1,391 shares of common stock, all held directly. No Rule 10b5-1 trading plan is reported for this award.
electroCore, Inc. (symbol: ECOR) is the issuer of record for a Form 4 filing submitted to the SEC. Wilber Patricia reported acquisition or exercise transactions in this Form 4 filing.
electroCore, Inc. (ECOR) reported that director Patricia Wilber received a grant of 11,123 Deferred Stock Units on September 9, 2026 as an annual equity award, at a stated price of $0.00 per unit. The award vests in 12 equal monthly installments, or fully earlier upon the next annual stockholder meeting or a change of control, subject to her continuous service. After this grant, she directly holds 83,448 shares, including 35,594 previously vested shares from earlier Restricted Stock Unit awards.
electroCore, Inc. (symbol: ECOR) is the issuer of record for a Form 4 filing submitted to the SEC. Bonfiglioli Elena reported acquisition or exercise transactions in this Form 4 filing.
electroCore, Inc. (ECOR) reported that director Elena Bonfiglioli received a grant of 11,123 Restricted Stock Units (RSUs) on September 9, 2026 as an annual director award. The RSUs vest in 12 equal monthly installments and fully vest earlier upon the next annual stockholder meeting or a change of control, subject to continuous service. Following this grant, Bonfiglioli holds 41,672 shares and RSUs in total, including 7,637 vested RSUs and 22,912 unvested RSUs. No Rule 10b5-1 trading plan is reported.
electroCore, Inc. (symbol: ECOR) is the issuer of record for a Form 4 filing submitted to the SEC. Fox Michael reported acquisition or exercise transactions in this Form 4 filing.
electroCore, Inc. (ECOR) reported that Co-Chief Executive Officer, President and Chief Operating Officer Michael Fox received a grant of 55,000 restricted stock units (RSUs) of Common Stock on September 8, 2026 as a compensation-related award. These RSUs vest one-third on the first anniversary of the grant date and the remaining two-thirds in equal annual installments over the following two years, subject to continued service and certain protections upon qualifying termination after a change in control under the company’s Executive Severance Policy. Following this grant, Fox directly holds 125,000 shares/RSUs, including 70,000 previously granted RSUs scheduled to vest in three annual tranches from April 13, 2027 through April 13, 2029. No transactions are reported under a Rule 10b5-1 trading plan.
electroCore, Inc. (symbol: ECOR) is the issuer of record for a Form 4 filing submitted to the SEC. Goldstein Julie Ann reported acquisition or exercise transactions in this Form 4 filing.
electroCore, Inc. (ECOR) director Julie Ann Goldstein reported an equity compensation grant of 11,123 shares of Common Stock in the form of Annual Deferred Stock Units on September 9, 2026, at a stated price of $0.00 per share, with no Rule 10b5-1 trading plan reported.
The Deferred Stock Units vest in 12 equal monthly installments from the grant date, or earlier in full before the next annual stockholder meeting or immediately prior to a change of control, subject to continuous service. Following this award, her reported holdings total 112,510 shares, including 29,011 vested Deferred Stock Units and 1,665 shares held through NeuroSpine Ventures, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.